Rebuilding The R&D Engine in Big Pharma  

Oleh:

Pierre Garnier, Jean

Jenis: Article from Bulletin/Magazine - ilmiah internasional
Dalam koleksi: Harvard Business Review bisa di lihat di link (http://web.b.ebscohost.com/ehost/command/detail?sid=f227f0b4-7315-44a4-a7f7-a7cd8cbad80b%40sessionmgr114&vid=12&hid=105&bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d#db=bth&jid=HBR) vol. 86 no. 5 (May 2008), page 68-77.
Topik: PHARMACY; rebuilding; R & D engine; big pharma

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: HH10.36 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Historically, the pharmaceutical industry has been a leader in financial performance and value creation. In recent years, however, its stock - market record has raised doubts about the sustainability of that history along with fundamental question about the industry's health. From December 2000 to February 2008 the top 15 companies in industry lost roughly $850 billion in shareholder value, and the price of their shares fell from 32 times earnings, on average, to 13. The common explanation for investors' loss of faith is well - known perfect strom of trends - pricing pressures, regulatory requirements, legal entanglements, inroads by generics, and declining R & D productivity - that have increased the industry's costs enormously and reduced its revenue and profit potential. I certainly agree that all of these trends are problems for the industry. But I believe that declining R & D productivity is at the center of its malaise.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali